Cangrelor: a review on pharmacology and clinical trial development

References

• Storey RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 12(7), 443–447 (2001).
   PubMed Web of Science ®Google Scholar
• Gachet C. ADP receptors of platelets and their inhibition. Thromb. Haemost. 86(1), 222–232 (2001).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ. J. 74(4), 597–607 (2010).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. The clopidogrel in unstable angina to prevent recurrent events trial investigators. effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd et al. CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med 357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009)
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D et al. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33(20), 2569–2619 (2012).
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S et al. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23), 2999–3054 (2011).
   PubMed Web of Science ®Google Scholar
• American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61(4), e78–e140 (2013).
   PubMed Web of Science ®Google Scholar
• Jneid H, Anderson JL, Wright RS et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 60(7), 645–681 (2012).
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J. Am. Coll. Cardiol. 58(24), e44–e122 (2011).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14),1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb. Haemost. 102(1), 7–14 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol. 63(1), 60–76 (2010).
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919–33 (2010).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. New directions in antiplatelet therapy. Circ. Cardiovasc. Interv. 5(3), 433–45 (2012).
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5(6), 797–804 (2012).
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B et al. Comparison of prasugrel and ticagrelor loading doses in st-segment elevation myocardial infarction patients: rapid (rapid activity of platelet inhibitor drugs) primary pci study. J. Am. Coll. Cardiol. 61(15), 1601–1606 (2013).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25), 2577–2585 (2009).
   PubMed Web of Science ®Google Scholar
• Price MJ, Walder JS, Baker BA et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J. Am. Coll. Cardiol. 59(25), 2338–2343 (2012).
   PubMed Web of Science ®Google Scholar
• Osmancik P, Jirmar R, Hulikova K et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc. Interv. 75(2), 158–166 (2010).
   PubMed Web of Science ®Google Scholar
• Heestermans AA, van Werkum JW, Taubert D et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb. Res. 122(6), 776–781 (2008).
   PubMed Web of Science ®Google Scholar
• Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev. Cardiovasc. Ther. 8(8), 1069–1077 (2010).
   PubMedGoogle Scholar
• Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev. Cardiovasc Ther. 7(10), 1195–201 (2009).
   PubMedGoogle Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest. 113(3), 340–345 (2004).
   PubMed Web of Science ®Google Scholar
• Hechler B, Vigne P, Léon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol. Pharmacol. 53(4), 727–733 (1998).
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey A et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem. 42(2), 213–220 (1999).
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31(2), 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Nassim MA, Sanderson JB, Clarke C et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers. J. Am. Coll. Cardiol. 33(2 Suppl. A), A255 (1999).
   Google Scholar
• Javis GE, Nassim MA, Humphries RG et al. The P2Y antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood 94(Suppl. 1), A22 (1999).
   Google Scholar
• Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J. Thromb. Haemost. 3(1), 85–92 (2005).
   PubMed Web of Science ®Google Scholar
• Storey RF, Oldroyd KG, Wilcox RGOpen multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndrome. Thromb. Haemost. 85(3), 401–407 (2001).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Ohman EM, Gibson CM et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am. Heart J. 154(4), 702–709 (2007).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J. 151(3), 689.e1–689.e10 (2006).
   Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123(7), 798–813 (2011).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Tello-Montoliu A et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. J. Thromb. Thrombolysis 35(2), 155–164 (2013).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121(4), 527–534 (2008).
   PubMed Web of Science ®Google Scholar
• Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost. 6(7), 1153–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y12 antagonists in an ex-vivo canine model. Thromb. Res. 130(4), 622–628 (2012).
   PubMed Web of Science ®Google Scholar
• Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J. Am. Coll. Cardiol. 49(22), 2145–2150 (2007).
   PubMed Web of Science ®Google Scholar
• Savonitto S, Caracciolo M, Cattaneo M, DE Servi S. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J. Thromb. Haemost. 9(11), 2133–2142 (2011).
   PubMed Web of Science ®Google Scholar
• Rossini R, Bramucci E, Castiglioni B et al. Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation. G. Ital. Cardiol. (Rome). 13(7–8), 528–551 (2012).
   PubMedGoogle Scholar
• Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284(12), 1549–1558 (2000).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ et al.; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307(3), 265–274 (2012).
   PubMed Web of Science ®Google Scholar
• Welsh RC, Rao SV, Zeymer U et al. INNOVATE-PCI Investigators. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ. Cardiovasc. Interv. 5(3), 336–346 (2012).
   PubMed Web of Science ®Google Scholar
• Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 6(4), 445–453 (2010).
   PubMedGoogle Scholar
• Harrington RA, Stone GW, McNulty S et al. Platelet Inhibition with Cangrelor in Patients Undergoing PCI. N. Engl. J. Med. 361(24), 2318–2329 (2009).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff M, Gibson M et al. Intravenous Platelet Blockade with Cangrelor during PCI. N. Engl. J. Med. 361(24), 2330–2341 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Schneider DJ, Bhatt DL et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J. Thromb. Thrombolysis 34(1), 44–55 (2012).
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP, Dauerman HL et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am. Heart J. 163(2), 182–90.e4 (2012).
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD et al. Universal definition of myocardial infarction. Circulation 116(22), 2634–2653 (2007).
   PubMed Web of Science ®Google Scholar
• Leonardi S, Mahaffey KW, White HD et al. Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet InhibitiON PHOENIX trial. Am. Heart J. 163(5), 768–776.e2 (2012).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW et al. CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368(14), 1303–1313 (2013).
   PubMed Web of Science ®Google Scholar
• Widimsky P, Motovská Z, Simek S et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur. Heart J. 29(12), 1495–1503 (2008).
   PubMed Web of Science ®Google Scholar